Sanofi (NASDAQ:SNY) Receives Average Recommendation of "Buy" from Analysts

Sanofi (NASDAQ:SNY - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $62.00.

SNY has been the subject of several research analyst reports. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd.

Hedge Funds Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNY. Price T Rowe Associates Inc. MD boosted its stake in Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Nuveen LLC bought a new position in Sanofi during the first quarter valued at approximately $177,831,000. Raymond James Financial Inc. boosted its stake in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company's stock valued at $284,058,000 after buying an additional 2,635,867 shares during the last quarter. Federated Hermes Inc. boosted its stake in Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after buying an additional 1,456,269 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new position in Sanofi during the first quarter valued at approximately $48,938,000. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of SNY opened at $49.77 on Monday. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a 50-day simple moving average of $48.57 and a two-hundred day simple moving average of $51.81. The stock has a market cap of $122.21 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 1.19 and a beta of 0.48. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%. The business's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.73 EPS. On average, analysts expect that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.